论文部分内容阅读
迄今为止,化学药物治疗(化疗)仍是急性白血病(acute leukemia,AL)治疗的主要方法,AL细胞对抗癌药物的耐药是AL化疗失败、疾病复发的一个主要根源。AL细胞耐药分为原药耐药(primary drug resistance,PDR)和多药耐药(multidrug re- sistance,MDR),其中自血病细胞对许多结构和功能都完全不同的药物的交叉耐药性(MDR)是AL的一种主要的耐药形式。由于AL患者的个体差异及白血病细胞的异质性,现在认为MDR的产生是多因素、多机制综合作用的结果。
To date, chemotherapeutic (chemotherapeutic) therapy remains the primary treatment for acute leukemia (AL), and AL cell resistance to anticancer drugs is a major source of AL chemotherapy failure and disease recurrence. AL cell resistance is divided into primary drug resistance (PDR) and multidrug resistance (MDR), in which many leukemia cells are cross-resistant to many drugs that are completely different in structure and function Sex (MDR) is a major drug-resistant form of AL. Due to the individual differences in AL patients and the heterogeneity of leukemia cells, the generation of MDR is now considered to be the result of a multifactorial, multi-mechanism combination.